George Samman, MD
Gynecology · Washington, DCNPI 1649215120
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.5%), consulting fees and education — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Scynexis, Inc. at 56.9% of the total. Reporting peaked in 2022 at $1,319 and has fallen 98.9% since, to $14 in 2024.
Across 52 payments — averaging $41.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Scynexis, Inc.$1K
- AbbVie$225
- Therapeuticsmd, Inc.$188
- Mylan Pharmaceuticals Inc.$152
- Pfizer$89
- Hologic Sales And Service, LLC$74
- plus $200 from 7 others
What the payments were for
- Consulting fees$1,00046%
- Food & beverage$1,13153%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Scynexis, Inc. | 6 | $1,227 |
| AbbVie(2 entities) | 11 | $225 |
| Therapeuticsmd, Inc. | 9 | $188 |
| Mylan Pharmaceuticals Inc. | 7 | $152 |
| Pfizer | 4 | $89 |
| Hologic Sales And Service, LLC | 3 | $74 |
| Avion Pharmaceuticals | 3 | $59 |
| Roche Diagnostics Corporation | 4 | $52 |
| Aspira Women's Health Inc | 1 | $24 |
| Mayne Pharma Commercial LLC | 1 | $19 |
| Evofem Biosciences, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $14 |
| Trevena, Inc. | 1 | $13 |
How this compares
Too few gynecology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ValacyclovirValacyclovir Hcl | 12 | $291 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $168 |
| Fluconazole | 43 | $152 |
| Triamcinolone Acetonide | 17 | $98 |
Paid to pharmacies, not to this prescriber.
Other gynecology in Washington
- Gaby MoawadWashington$1.5M
- James SimonWashington$811K
- Anthony ScialliWashington$165K
- Andrew GoldsteinWashington$156K
- Marilyn JeromeWashington$14K
- Erica DavenportWashington$13K
- Julian SafranWashington$6K
- Sharon MaloneWashington$3K
- Alyssa Small LayneWashington$3K
- Bandhana BajajWashington$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.